Back

Impact of semaglutide on mortality, cardiovascular, and kidney outcomes across the cardio-kidney-metabolic continuum: a meta-analysis of randomized controlled trials

31 August 2026 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Cardiometabolic pharmacotherapy and cardiovascular outcomes Antidiabetic Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Ciro Cotticelli

University of Naples Federico II, Naples (Italy)

5 More presentations in this session

Presentation thumbnail
B-type natriuretic peptide level reduction and its predictors following sodium-glucose cotransporter 2 inhibitor treatment in patients with diabetic kidney disease
Doctor T. Nagahiro (Yokohama, JP)
Abstract
Presentation thumbnail
Cardiovascular and renal outcomes of Semaglutide in patients with Type 2 Diabetes Mellitus with established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease: A Meta-Analysis
Doctor F. Lumancas (Cebu City, PH)
Abstract
Presentation thumbnail
Effects of luseogliflozin on sympathetic nerve activity:a dual assessment using iodine-123-metaiodobenzylguanidine and muscle sympathetic nerve activity
Mr T. Hirai (Kanazawa, JP)
Abstract
Presentation thumbnail
Comparative cardiovascular efficacy of individual GLP-1 receptor agonists and tirzepatide: a Bayesian network meta-analysis of 13 cardiovascular outcome trials
Ms Y. Srivastava (IN)
Abstract
Presentation thumbnail
Regression of microalbuminuria predicts cardiovascular risk reduction with GLP-1 receptor agonist therapy
Doctor I. Figueroa Baez (San Juan, PR)
Abstract

Access the full session

Session thumbnail
Cardiometabolic pharmacotherapy and cardiovascular outcomes

The Event

Event poster

ESC Congress 2026

31 August 2026 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Risk of death with sodium-glucose co-transporter-2 inhibitors across the hallmark cardiovascular and renal outcome trials: an updated meta-analysis
27 August 2021
thumbnail
Congress Presentation
Effects of semaglutide on functional capacity in patients with type 2 diabetes and peripheral arterial disease: rationale and design of the STRIDE trial
27 August 2021
thumbnail
Congress Presentation
Efficacy and safety of GLP-1 agonists in obesity-related heart failure with preserved ejection fraction: a systematic review and meta-analysis of randomized placebo-controlled trials.
1 September 2025
thumbnail
Congress Presentation
Comparison of cardiovascular outcomes in patients with diabetes treated with tirzepatide versus semaglutide: a multi-institutional analysis
31 August 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources